Radar Telegram alerts Open Radar

Immutep reports encouraging disease-free survival from the EFTISARC-NEO Phase II trial in soft tissue sarcoma.

תרגם לעברית

Business Insider Markets · · Source

Immutep reports encouraging disease-free survival from the EFTISARC-NEO Phase II trial in soft tissue sarcoma.

More on Radar

Want to see every report in real time?

Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.

Sign up free
Share on WhatsApp Get alerts on Telegram